RxDoctor Payments DataLook up a doctor →

Gonzalo Hidalgo, MD

Neurology · Alexandria, LANPI 1679640254

Payments from drug & device makers

$260,319in general payments, 2019–2025

Across 1,737 payments — averaging $149.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$186K
  • Sunovion Pharmaceuticals Inc.$25K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$17K
  • Eli Lilly$8K
  • Acadia Pharmaceuticals Inc$3K
  • Biogen$2K
  • plus $20K from 54 others
$7,000in research payments, 2019–2025

Across 1 payment — averaging $7000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$7K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)383$185,559
Sunovion Pharmaceuticals Inc.4$24,646
Otsuka Pharmaceutical Development & Commercialization, Inc.2$17,500
Eli Lilly5$7,924
Acadia Pharmaceuticals Inc256$2,785
Biogen83$1,885
Pfizer45$1,728
UCB, Inc.92$1,728
Amgen(2 entities)87$1,558
Sanofi58$1,473
EMD Serono, Inc.50$1,001
Eisai Inc.49$977
Novartis52$886
AstraZeneca47$831
Bristol Myers Squibb45$645
Lilly USA, LLC29$636
SK Life Science, Inc.28$543
Lundbeck LLC30$505
Argenx US, Inc.22$495
Biohaven Pharmaceuticals, Inc.44$491
E.r. Squibb & Sons, L.L.C.9$479
Amneal Pharmaceuticals LLC33$450
Acorda Therapeutics, Inc22$438
Neurocrine Biosciences, Inc.21$373
Biohaven Pharmaceutical Holding Company Ltd.28$371
Teva Pharmaceuticals USA, Inc.28$359
Saol Therapeutics Inc.9$345
Otsuka America Pharmaceutical, Inc.13$330
Mallinckrodt Hospital Products Inc.14$322
Johnson & Johnson(2 entities)6$276
MDD US Operations, LLC15$274
TG Therapeutics, Inc.15$266
Jazz Pharmaceuticals Inc.9$188
Sumitomo Pharma America, Inc.10$174
Genentech USA, Inc.8$168
Takeda Pharmaceuticals U.S.A., Inc.7$168
Boston Scientific4$124
Neurelis, Inc.5$116
Kyowa Kirin, Inc.4$105
Merz Pharmaceuticals, LLC5$101
Catalyst Pharmaceuticals, Inc.5$95
Livanova USA, Inc.4$93
CSL Behring4$88
Adamas Pharmaceuticals, Inc.5$77
Hospira, Inc.4$70
Mallinckrodt Enterprises LLC4$68
Supernus Pharmaceuticals, Inc.4$65
Tanabe Pharma America, Inc.4$63
Ipsen Biopharmaceuticals, Inc3$58
Grifols USA, LLC3$54
Arbor Pharmaceuticals, Inc.4$53
Currax Pharmaceuticals LLC3$46
ANI Pharmaceuticals, Inc.2$46
Sanofi-aventis U.S. LLC2$41
Vanda Pharmaceuticals Inc.1$35
Cycle Pharmaceuticals Inc1$28
Avanir Pharmaceuticals, Inc.2$27
Harmony Biosciences LLC1$18
Ultragenyx Pharmaceutical Inc.1$17
Alnylam Pharmaceuticals Inc.1$14

How this compares

$260,319 in reported general payments places this provider in the 90th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana →

Medicare billing

Part B allowed, 2024
$571,033
Medicare patients
866
Services billed
20,410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Alexandria

See the full list for Louisiana →

Where these figures come from

Is this you, or does something look wrong? →